# Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

> **NCT00426361** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 751 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Boostrix ® Polio
- **BIOLOGICAL:** GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)

## Key facts

- **NCT ID:** NCT00426361
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-13
- **Primary completion:** 2008-03-17
- **Final completion:** 2008-07-25
- **Target enrollment:** 751 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426361, "Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00426361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*